Improved Tablet  Focus on stability  Focus on reasonable production  Focus on packaging material High-End Tablet  Vision?! Study Medication  Focus.

Slides:



Advertisements
Similar presentations
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
Advertisements

1st lecture MSc. Ikhlas Jarrar
SAKATA INX SAKATA INX SAKATA INX (INDIA) LTD TECHNICAL TRAINING - OFFSET INKS & VENUE : UNITECH - I COUNTRY CLUB, GURGAON TOPIC.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Soft cosmetic products, creams. Suspensions, gels.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
Antiperspirants and Deodorants. Formulation Examples and Forms of Applications: 1.Aerosols: Active ingredients + liquid gas {as propellants} placed into.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pharmaceutical Excipients
Reference, Retention and Reserve Samples
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Fine Chemicals Division Human Nutrition Helping Make Products More Nutritious Nano-scale Formulations of Health Ingredients Dr. Lutz End Fine Chemicals.
World Health Organization
PRINCIPLES OF COMPOUNDING
PVC (polyvinyl chloride)
European Biomass Industry Association EU BC&E, 25 june 2014, Hamburg, Germany ALGADISK –Novel algae-based solution for CO 2 capture and biomass production.
University of Medicine and Pharmacy „Iuliu Haţieganu”, Faculty of Pharmacy Department of Pharmaceutical Technology and Biopharmaceutics, , Cluj-Napoca,
Large-Scale Integrating Project SEVENTH FRAMEWORK PROGRAMME THEME 1: HEALTH Optimization of Treatment and Management of Schizophrenia in Europe WP2 medication.
Factors Affecting Drug Absorption (Pharmaceutical factor)
PRODUCT TRANSFER.
Clonazepam  relieve panic attacks IUPAC Name: 5-(2-chlorophenyl)-1,3-dihydro-7- nitro-2H-1,4- benzodiazepin-2-one Molecular weight: Appearance:
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
D699BC00001(FALCON) Drug Supply.
OR “READ THE FINE PRINT PLEASE!”
Novel Multifunctional Excipients by Co-processing with Mg-Silicate Dr. Faisal Al-Akayleh Faculty of Pharmacy, Petra University.
1.  Drug delivery is the method or process of administering pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Most common.
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
 Objectives / Deliverables  Strategy  Ideas  First Results  Recent and Next Steps G&H Meeting th April, 2002 Leipzig, Germany WP 7 Pharmaceutics.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Study Medication  Time schedule  Résumé Development of an improved tablet formulation  Long term stability  Reasonable production conditions  Focus.
Stability Trials ASEAN Guidelines. The Objective of a stability study To determine the shelf life, namely the time period of storage at a specified condition.
DH 29  Development of analytical methods DH 30  Analysis of EU market products DH 33  Development of a novel tablet DH 36  Preparation of study medication.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
1 G&H Meeting 4-5 th October, 2001 G&H Meeting 4-5 th October, 2001 Wellesbourne, UK Wellesbourne, UK WP 7 Pharmaceutics WP 7 Pharmaceutics Objectives.
Tablets coating.
Solid dosage forms Tablets
Suad Y. Alkarib 1 Dina Elraih 2 Waddah F. Nour 3.
Pharmaceutical Quality Control & current Good Manufacturing Practice PHT 436 Lecture 11 1.
 Objectives Improved Tablet  focus on stability  focus on low costs High-End Tablet  maximum dose  controlled release G&H Meeting 1-2 October, 2002.
AktieTorgets investerarfrukost 17 september 2015 David Westberg, CEO.
Ichem Ltd. is a Polish manufacturer of food supplements and cosmetics on a contract basis.
{ Medical Review Doses and Terminology Part 2.  Solid dosage forms which have been crushed to make a fine powder  Can be used internally or externally.
NICNAS Reforms Treatment of Confidential Commercial Information Workshop.
HOLD-TIME STUDIES.
Quality by Design Approach for an Immediate Release Tablet
- Pharmaceutical Equivalence Study
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
ASSESSMENT OF THE IMPACT OF HUMIDITY ON STABILITY OF APOTRIAVIR TABLETS AND ITS IMPLICATION IN BETTER TASTE RELEASE TRACPlus 2010 KIGALI, November 11,
Solid dosage forms Tablets
PRINCIPLES OF PHARMACEUTICAL FORMULATION AND DOSAGE FORM DESIGN:
Gastrointestinal Absorption: Role of the Dosage Form
Evaluation of tablet Lab 5.
Evaluation of tablet Lab 5.
Novel Drug Delivery System
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
FARHANA AMIRAH NADIA AMIR
The Art of Baking.
RAPID RELIABLE RESULTS
Objectives… G&H Meeting February, 2003 Liverpool, UK
Quality control Lecture 1.
Evaluation of tablet Lab 5.
Clinical Trials of Vaccines and Drugs
Practical Pharmaceutical Orientation
RingCap Technology Mrs. Maria Saifee Associate Professor,
Tablets.
Manufacturing, Marketing Pharmaceutical development
Presentation transcript:

Improved Tablet  Focus on stability  Focus on reasonable production  Focus on packaging material High-End Tablet  Vision?! Study Medication  Focus on time line  Focus on GCP compliance G&H Meeting February, 2003 Liverpool, UK WP 7 Pharmaceutics (Lichtwer Pharma)  Objectives…

Improved Tablet Improved Tablet  Comparing  Comparing…  Dragee (Market Standard)  300 mg Garlic powder  Higher amounts of excipients  Coating time: up to 15 h  Total process time: up to 24 h  Novel film coated tablet  300 mg Garlic powder  Less amounts of excipients (pre dried)  Coating time:  up to 5 h  Total process time: up to 14 h  Advantages of a film tablet…  Size (Compliance)  Costs for Excipients  Costs for Production (time)

Improved stabile Tablet Improved stabile Tablet  Details on Stability Study  Full ICH-guideline compliance -Tests under GMP conditions with validated methods -Three production batches providing a minimum of tablets per batch -Three different controlled climatic zones  Up to seven different packaging materials -PVC-, PVDC, COC-Aluminium blister -Two different kinds of Alu-Alu blisters -PE-, and glass bottles  Two different dosage forms -100 mg and 300 mg Tablets  Estimated full costs for the study: 160 k€

Dragees (Commercial Products) 25°C/60% and 40°C/75% Commercial products are insufficient !!!

Comparison Powder/Dragees 25 °C / 60% r.h. Proof that commercial tablet formulations are sub optimal

 Comparing… Commercial Dragee vs. Novel Film Tablet  Dragee  300 mg Garlic powder  117 mgLactose monohydrate  9 mgCellulose  5 mgSilicium dioxide  3 mgMg Stearate  224 mgSaccharose  46 mgTalcum  22 mgHPMC (mod. Cellulose)  9 mgCastor oil, native  5 mgPolyethylenglycol  5 mgPolyvinylpyrrolidon  2 mgSilicium dioxide  2 mg Gelatine  1 mgMontan glycol wax  750 mgTotal Weight  Novel film coated tablet  300 mg Garlic powder  117 mgmicrocristalline Cellulose  24 mgLactose, anhydrous  10 mgCellulose  5 mgSilicium dioxide  6 mg Soy polysaccharides  3 mgTriglycerides  25 mgHPMC (mod. Cellulose)  5 mgTalcum  4 mg Titan dioxide  1 mg Carnauba wax  500 mgTotal Weight

Comparison Tablets with lyophilisised/non lyophilisised Powder/Dragees 25 °C / 60% r.h. Improvement of Stability of at least >100%

Comparison Packaging Material 25 °C / 60% r.h.

Comparison Packaging Material 30 °C / 70% r.h.

Comparison Packaging Material 40 °C / 75% r.h. Conclusion -at least 24 months stability available -countries with difficult climatic conditions included!

Comparison Packaging Material 25 °C / 75% r.h. – 300 mg Tablets

Comparison Packaging Material 30 °C / 70% r.h. – 300 mg Tablets

Comparison Packaging Material 40 °C / 75% r.h. – 300 mg Tablets

Comparison Blister Material 25 °C / 60% r.h. – 300 mg Tablets

Improved Tablet Improved Tablet  Sugar coated tablets are not suitable to meet the high international standards of pharmaceutical stability  No kind of transparent polymer blister quality provide sufficient protection  A strict dry formulation (ingredients and process) combined with…  a 100% water vapour resistant packaging …are indispensable  Conclusion

High-End Tablet High-End Tablet  Laboratory experiments to gain a alliin enriched extract were successful  4-5 fold enrichment of alliin (up to 7%in total) without transformation to allicin by an economic single-step extraction procedure  Extract seems to be suitable for direct use for production (“crystalline like” – not sticky)  Scale up experiments – still open  Garlic powder combined with a alliin rich extract

High-End Tablet High-End Tablet  Development of a slow release matrix tablet – open  Additional development time of 9-15 months is necessary (only with orientating stability data)  Realisation: not really realistic – see end of the project in Jan 2004!  Garlic powder combined with an alliin rich extract

Study medication Human Intervention Study Study medication Human Intervention Study  Three arm study – double blind performing a double dummy design  Verum: Garlic powder tablets Reference: Statin medication (Cholesterol- Synthesis-Inhibitor Placebo:for Garlic tablets and for statin medication  30 Volunteers in each group; 2100 mg garlic powder a day; Treatment over 100 days  Medication produced and packed under GMP

 Formulation – Study medication  “Film-Dragee”  300 mg Garlic powder  187 mgLactose anhydrous  25 mgCellulose  4 mgSilicium dioxide  4 mgMg Stearate  ca. 40 mgMethacrylic acid copolymer  ca. 10 mgCitric acid  ca. 5 mg Talcum  224 mgSaccharose  46 mgTalcum  5 mgPolyethylenglycol  5 mgPolyvinylpyrrolidon  2 mgSilicium dioxide  2 mg Gelatine  1 mgMontan glycol wax  Ca. 800 mgTotal weight Tablet core Gastric resistant film Sugar coating

Study medication Human Intervention Study Study medication Human Intervention Study  Verum: Tablet design Tablet Core Gastric Fluid Resistant Coating Sugar Coating „Dragee“

Study medication Time schedule Study medication Time schedule  7 th -8 th WeekProduction Verum & Placebo  7 th -8 th WeekWriting & Authorisation production protocol  9 th -10 th WeekWriting Randomisation Plan  9 th -10 th WeekQuality Control Verum & Placebo  10 th -11 th WeekWriting & Authorisation packaging/ labelling  12 th WeekPackaging & Labelling  13 th -14 th WeekFinal Release & Delivery

Thanks for listening!!! Thanks for listening!!! Anybody who fell asleep? Fine!